{"id":"W4387339999","doi":"10.1016/j.annonc.2023.09.3110","title":"Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"MSD Italia; Eisai; Incyte; AstraZeneca; Les Laboratories Pierre Fabre; Gilead Sciences; Clovis Oncology; Servier; Pfizer","keywords":"Medicine; Olaparib; PARP inhibitor; Ovarian cancer; Oncology; Internal medicine; Cancer; Poly ADP ribose polymerase; Polymerase; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001281656,0.0006840006,0.001451915,0.0001895758,0.0002956517,0.0005584714,0.0005455454,0.0007026758,0.001937924],"category_scores_gemma":[0.0007402343,0.0003114859,0.001258078,0.0002590347,0.0006105458,0.0004991588,0.0002760063,0.001589923,0.0002582993],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005174335,"about_ca_system_score_gemma":0.0007738987,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004586829,"about_ca_topic_score_gemma":0.001580762,"domain_scores_codex":[0.9997042,0.0001295722,0.00002472757,0.00005410101,0.00002935303,0.00005812605],"domain_scores_gemma":[0.9995775,0.00007909789,0.00009748153,0.00004348586,0.00001942065,0.0001830823],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8456182,0.01786269,0.01169819,0.001071661,0.001641892,0.0002648454,0.0001557127,0.001096302,0.02150646,0.0002134031,0.002098098,0.09677245],"study_design_scores_gemma":[0.7287079,0.2462709,0.01912069,0.00007067325,0.0006046629,0.000355021,0.00003367845,0.0008374719,0.001748935,0.0001928292,0.002034002,0.00002326912],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939551,0.003510859,0.0002076129,0.0002445235,0.00008004555,0.0009467625,0.0002852522,0.00004023942,0.0007295905],"genre_scores_gemma":[0.9948396,0.001709911,0.0005343275,0.0004201572,0.0001011472,0.0008595999,0.0007167251,0.00000707102,0.0008114731],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001937924,"threshold_uncertainty_score":0.006778061,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07819275097947659,"score_gpt":0.3885708198044928,"score_spread":0.3103780688250162,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}